16-2-2-3　ⓔ文献

  1. Cavalot F, Pagliarino A, et al: Postprandial blood glucose predicts cardiovascular events and all–cause mortality in type 2 diabetes in a 14–year follow–up: Lessons from the San Luigi Gonzaga diabetes study. Diabetes Care, 2011; 34: 2237–2243.

  2. 門脇　孝：間歇スキャン持続グルコースモニタリングシステム―FreeStyleリブレに関する見解 (改訂第3版)，2020．

  3. The Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long–term complications: the perspective of the diabetes control and complications trial. Diabetes, 1996; 45: 1289–1298.

  4. Stratton IM, Adler AI, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J, 2000; 321: 405–412.

  5. Ohkubo Y, Kishikawa H, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non–insulin–dependent diabetes mellitus a randomized prospective 6–year study. Diabetes Res Clin Pract, 1995; 28: 103–117.

  6. Holman RR, Paul SK, et al: 10–year follow–up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359: 1577–1589.

  7. Gerstein HC, Miller ME, et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358: 2545–2559.

  8. Hansson L, Zanchetti A, et al: Effects of intensive blood–pressure lowering and low–dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998; 351: 1755–1762.

  9. Turner R, Holman R, et al: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J, 1998; 317: 703–713.

  10. 日本人の肥満2型糖尿病患者に対する減量・代謝改善手術の適応基準に関する3学会合同委員会：日本人の肥満2型糖尿病患者に対する減量・代謝改善手術に関するコンセンサスステートメント，コンパス出版局，2021．

  11. Wheeler ML, Dunbar SA, et al: Macronutrients, food groups, and eating patterns in the management of diabetes. Diabetes Care, 2012; 35: 434–445.

  12. Meng Y, Bai H, et al: Efficacy of low carbohydrate diet for type 2 diabetes mellitus management: A systematic review and meta–analysis of randomized controlled trials. Diabetes Res Clin Pract, 2017; 131: 124–131.

  13. Snorgaard O, Poulsen GM, et al: Systematic review and meta–analysis of dietary carbohydrate restriction in patients with type 2 diabetes. BMJ Open Diabetes Res Care, 2017; 5: e000354.

  14. van Wyk HJ, Davis RE, et al: A critical review of low–carbohydrate diets in people with type 2 diabetes. Diabet Med, 2016; 33: 148–157.

  15. Yao B, Fang H, et al: Dietary fiber intake and risk of type 2 diabetes: a dose–response analysis of prospective studies. Eur J Epidemiol, 2014; 29: 79–88.

  16. Fujii H, Iwase M, et al: Impact of dietary fiber intake on glycemic control, cardiovascular risk factors and chronic kidney disease in Japanese patients with type 2 diabetes mellitus : the Fukuoka Diabetes Registry. Nutr J, 2013; 12: 1–8.

  17. Pedersen AN, Kondrup J, et al: Health effects of protein intake in healthy adults: a systematic literature review. Food Nutr Res, 2013; 57: 21245.

  18. Becerra–tom N, Ruiz–canela M, et al: Total and subtypes of dietary fat intake and risk of type 2 diabetes mellitus in the Prevención con Dieta Mediterránea (PREDIMED) study. Am J Clin Nutr, 2017; 105: 723–735.

  19. Wang L, Folsom AR, et al: Plasma fatty acid composition and incidence of coronary heart disease in middle aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Nutr Metab Cardiovasc Dis, 2003; 13: 256–266.

  20. Hodge AM, English DR, et al: Plasma phospholipid and dietary fatty acids as predictors of type 2 diabetes: Interpreting the role of linoleic acid. Am J Clin Nutr, 2007; 86: 189–197.

  21. Harding AH, Day NE, et al: Dietary fat and the risk of clinical type 2 diabetes: The European Prospective Investigation of Cancer–Norfolk Study. Am J Epidemiol, 2004; 159: 73–82.

  22. Mente A, Donnell MO, et al: Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension : a pooled analysis of data from four studies. Lancet, 2016; 388: 465–475.

  23. Ravussin E: A NEAT way to control weight? Science, 2005; 307: 530–531.

  24. Inagaki N, Gonoi T, et al: Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science, 1995; 270: 1166–1170.

  25. インクレチン (GLP–1受容体作動薬とDPP–4阻害薬) の適正使用に関する委員会：「インクレチン (GLP–1受容体作動薬とDPP–4阻害薬) の適正使用に関する委員会」から，2011．http://www.fa.kyorin.co.jp/jds/uploads/photos/797

  26. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev, 2005; 26: 439–451.

  27. Loke YK, Singh S FC: Long–term use of thiazolidinediones and fractures in type 2 diabetes: a meta–analysis. Cmaj, 2009; 180: 32–39.

  28. Neumann A, Weill A, et al: Pioglitazone and risk of bladder cancer among diabetic patients in France: A population–based cohort study. Diabetologia, 2012; 55: 1953–1962.

  29. ビグアナイド薬の適正使用に関する委員会：メトホルミンの適正使用に関する Recommendation，2019．http://www.fa.kyorin.co.jp/jds/uploads/recommendat

  30. SGLT2阻害薬の適正使用に関する委員会：SGLT2阻害薬の適正使用に関する Recommendation，2019．http://www.fa.kyorin.co.jp/jds/uploads/recommendat